Prelude Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Prelude Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-121,912	Closed	-$573K	–	1289
2026 Q1	$573K	Sell	121,912 -84,614	-41%	-$429K	0.04%	458
2025 Q4	$880K	Hold	206,526	–	–	0.06%	355
2025 Q3	$659K	Buy	+206,526	New	+$465K	0.05%	428
2020 Q4	–	Sell	-1,700	Closed	-$11K	–	1400
2020 Q3	$11K	Buy	1,700 +1,300	+325%	+$9.64K	﹤0.01%	1439
2020 Q2	$3K	Buy	+400	New	+$3.71K	﹤0.01%	1778
2019 Q3	–	Sell	-611	Closed	-$7K	–	1762
2019 Q2	$7K	Buy	+611	New	+$6.41K	﹤0.01%	1456
2018 Q4	–	Sell	-72	Closed	-$1K	–	1837
2018 Q3	$1K	Sell	72 -10,385	-99%	-$237K	﹤0.01%	1682
2018 Q2	$239K	Buy	10,457 +9,254	+769%	+$236K	0.02%	713
2018 Q1	$34K	Buy	1,203 +802	+200%	+$22.9K	﹤0.01%	1178
2017 Q4	$8K	Buy	+401	New	+$8.31K	﹤0.01%	1229
2017 Q3	–	Sell	-300	Closed	-$5K	–	1669
2017 Q2	$5K	Buy	+300	New	+$4.52K	﹤0.01%	1464

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Prelude Capital Management's CTMX Position: Q2 2026 in Review

Prelude Capital Management sold out of CytomX Therapeutics (CTMX) in Q2 2026, closing a stake of 121,912 shares — an estimated $573K sold.

Prelude Capital Management first reported a position in CTMX in Q2 2017 and held it in 11 quarters. The position peaked at $880K in Q4 2025. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Prelude Capital Management reported no remaining CytomX Therapeutics position as of Q2 2026 after selling out during the quarter.
Prelude Capital Management sold 121,912 CytomX Therapeutics shares in Q2 2026, an estimated $573K.
Prelude Capital Management first reported a position in CytomX Therapeutics in Q2 2017 and held it in 11 quarters.
Prelude Capital Management's CytomX Therapeutics position peaked at $880K in Q4 2025.
178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.